ReviewOncoTargets and therapy2018
Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date.
Takaki Akamine et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
29 papers cite it
this papertrialcites it